Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline Pharmaceuticals Ltd.

Division of GlaxoSmithKline PLC
www.gsk-india.com

Latest From GlaxoSmithKline Pharmaceuticals Ltd.

India’s Paracetamol Exports Hit By Coronavirus Fallout

India permits medicines placed on a restricted list to be exported from SEZs and under advance licenses, but paracetamol exporters hope for more easing as restrictions begin to hurt. Meanwhile, the government asks industry to ensure four months of stock as it balances medicines security with economic interest.

Policy & Regulation Coronavirus COVID-19

Coronavirus Fallout: India’s Paracetamol Exports Hit

India permits medicines placed on a restricted list to be exported from SEZs and under advance licenses, but paracetamol exporters hope for more easing as restrictions begin to hurt. Meanwhile, the government asks industry to ensure four months of stock as it balances medicines security with economic interest.

Policy & Regulation Coronavirus COVID-19

Coronavirus Actions: How Pharma In India Is Handling Safety, Business Continuity

Scrip contacted a cross section of pharma firms in India to get a sense of how they are handling the extraordinary work-operations-employee well-being situation amid the coronavirus outbreak. Work from home mandates, deploying digital tools wherever possible, cut-back in field activities and daily temperature checks at sites are some of the initiatives set in motion.

Commercial Coronavirus COVID-19

Ranitidine Recall Dents GSK India, Which Mulls Plant Sale

GlaxoSmithKline India’s Vemgal plant, which entailed a large investment outlay, may be put on the block as part of a review of assets impacted by the recall of ranitidine over NDMA impurity concerns. The site, which has “all relevant approvals”, has not made commercial supplies yet.

India Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • GlaxoSmithKline PLC
  • Senior Management
  • Hasit Joshipura, Chmn.
    S. Khanna, VP, Fin.
  • Contact Info
  • GlaxoSmithKline Pharmaceuticals Ltd.
    Phone: (91) 22-2495-9595
    Dr. Annie Besant Rd.
    Mumbai,
    India
UsernamePublicRestriction

Register